Literature DB >> 28593514

Influence of Formulation Factors on the Aerosol Performance of Suspension and Solution Metered Dose Inhalers: A Systematic Approach.

Poonam Sheth1,2, Dennis Sandell3, Denise S Conti4, Jay T Holt5,6, Anthony J Hickey5,7, Bhawana Saluja4,8.   

Abstract

Metered dose inhalers (MDIs) are complex drug-device combination products widely used to treat pulmonary disorders. The efficacy, driven by aerosol performance of the products, depends on a multitude of factors including, but not limited to, the physicochemical properties of drug and nature and amount of excipient(s). Under the quality by design (QbD) paradigm, systematic investigations are necessary to understand how changes in critical quality attributes (CQAs) of formulation, device, and manufacturing process influence key product performance parameters, such as delivered dose (DD) and fine particle dose (FPD). The purpose of this work is to provide a better understanding of the effects of different levels of excipients and drug particle size distribution on the aerosol performance of MDI products, while using two fundamentally different MDI products as relevant model systems, Proventil® HFA (albuterol sulfate suspension) and Qvar® (beclomethasone dipropionate solution). These MDI products, as model systems, provided mid-points around which a design of experiments (DOE), consisting of 22 suspension and 9 solution MDI formulations, were defined and manufactured. The DOE included formulations factors with varying ethanol (2 to 20% w/w and 7 to 9% w/w for the suspension and solution, respectively) and oleic acid concentrations (0.005 to 0.25% w/w and 0 to 2% w/w for the suspension and solution, respectively) and drug volumetric median particle size distribution (PSD D50, 1.4 to 2.5 μm for the suspension). The MDI formulations were analyzed using compendial methods to elucidate the effect of these formulation variables (ethanol, oleic acid, and PSD D50) on DD and FPD. The outcomes of this study allowed defining design spaces for the formulation factors, such that DD and FPD would remain within specific pre-defined requirements. The systematic approach utilized in this work can contribute as a QbD tool to evaluate the extent to which the formulation factors govern the aerosol performance of MDI drug products, helping to design MDI formulations with desired product performance parameters.

Entities:  

Keywords:  albuterol sulfate; beclomethasone dipropionate; delivered dose; design of experiments; design spaces; excipients; fine particle dose; mathematical models; metered dose inhalers

Mesh:

Substances:

Year:  2017        PMID: 28593514     DOI: 10.1208/s12248-017-0095-3

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  20 in total

1.  Effect of Device Design and Formulation on the In Vitro Comparability for Multi-Unit Dose Dry Powder Inhalers.

Authors:  Jagdeep Shur; Bhawana Saluja; Sau Lee; James Tibbatts; Robert Price
Journal:  AAPS J       Date:  2015-05-09       Impact factor: 4.009

2.  Quality by design: concepts for ANDAs.

Authors:  Robert A Lionberger; Sau Lawrence Lee; Laiming Lee; Andre Raw; Lawrence X Yu
Journal:  AAPS J       Date:  2008-05-09       Impact factor: 4.009

Review 3.  Understanding pressurized metered dose inhaler performance.

Authors:  James W Ivey; Reinhard Vehring; Warren H Finlay
Journal:  Expert Opin Drug Deliv       Date:  2014-12-13       Impact factor: 6.648

4.  Comparison of optical particle sizing and cascade impaction for measuring the particle size of a suspension metered dose inhaler.

Authors:  Yu Pu; Lukeysha C Kline; Nazia Khawaja; Melissa Van Liew; Julianne Berry
Journal:  Drug Dev Ind Pharm       Date:  2014-03-19       Impact factor: 3.225

5.  Aerosol particle generation from solution-based pressurized metered dose inhalers: a technical overview of parameters that influence respiratory deposition.

Authors:  Bing Zhu; Daniela Traini; Paul Young
Journal:  Pharm Dev Technol       Date:  2014-09-22       Impact factor: 3.133

6.  Factors influencing aerodynamic particle size distribution of suspension pressurized metered dose inhalers.

Authors:  Poonam Sheth; Stephen W Stein; Paul B Myrdal
Journal:  AAPS PharmSciTech       Date:  2014-10-02       Impact factor: 3.246

7.  The pharmacokinetics of inhaled hydrofluoroalkane formulations.

Authors:  L Borgström
Journal:  J Allergy Clin Immunol       Date:  1999-12       Impact factor: 10.793

8.  Inhaler devices: what remains to be done?

Authors:  Ian J Smith; John Bell; Nic Bowman; Mark Everard; Stephen Stein; Jeffry G Weers
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-12       Impact factor: 2.849

9.  Solvation in hydrofluoroalkanes: How can ethanol help?

Authors:  Denise S Conti; Jordan Grashik; Lin Yang; Libo Wu; Sandro R P da Rocha
Journal:  J Pharm Pharmacol       Date:  2011-11-18       Impact factor: 3.765

10.  Tuning aerosol particle size distribution of metered dose inhalers using cosolvents and surfactants.

Authors:  Imran Y Saleem; Hugh D C Smyth
Journal:  Biomed Res Int       Date:  2013-07-24       Impact factor: 3.411

View more
  1 in total

Review 1.  Addressing the Regulatory and Scientific Challenges with Generic Orally Inhaled Drug Products.

Authors:  Bryan Newman; Kimberly Witzmann
Journal:  Pharmaceut Med       Date:  2020-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.